anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND OBJECTIVES: The aim of this study was to determine the role of site-specific metastatic patterns over time and assess factors associated with extended survival in metastatic PDAC. Half of all patients with pancreatic ductal adenocarcinoma (PDAC) present with metastatic disease. The site of metastasis plays a crucial role in clinical decision making due to its prognostic value.
METHODS: We examined 56,757 stage-IV PDAC patients from the National Cancer Database (2016-2019), categorizing them by metastatic site: multiple, liver, lung, brain, bone, carcinomatosis, or other. The site-specific prognostic value was assessed using log-rank tests while time-varying effects were assessed by Aalen's linear hazards model. Factors associated with extended survival (>3years) were assessed with logistic regression.
RESULTS: Median overall survival (mOS) in patients with distant lymph node-only metastases (9.0 months) and lung-only metastases (8.1 months) was significantly longer than in patients with liver-only metastases (4.6 months, p < 0.001). However, after six months, the metastatic site lost prognostic value. Logistic regression identified extended survivors (3.6 %) as more likely to be younger, Hispanic, privately insured, Charlson-index <2, having received chemotherapy, or having undergone primary or distant site surgery (all p < 0.001).
CONCLUSION: While synchronous liver metastases are associated with worse outcomes than lung-only and lymph node-only metastases, this predictive value is diminished after six months. Therefore, treatment decisions beyond this time should not primarily depend on the metastatic site. Extended survival is possible in a small subset of patients with favorable tumor biology and good conditional status, who are more likely to undergo aggressive therapies.
1316556 Topical base WARNER-LAMBERT CO 11 Feb 1972 [25 Feb 1971] 6505/72 Heading A5B A topical base for steroids comprises a mixture of ethanol, propylene glycol and water, gelled with an acidic carboxyvinyl polymer e.g. Carbopol (trade mark) which has been neutralised with an amine e.g. diisopropanolamine. The base may also contain disodium edetate, a stabiliser for the carboxyvinyl polymer. A topical ointment comprises the base and a steroid e.g. the anti-inflammatory betamethasone 17-benzoate.
The invention lies in the field of nanomedicine. It is able to release anti-inflammatory drug and anti-tumor drug according two different environment: the inflammatory condition in early stage of cancers, and the acid condition which has specific pH value after appearing of tumour cells.Gelatin as one kind of nano-drug carrier is a polysaccharide which can be absorbed after releasing all nano-drugs. Poly(ethylene glycol) as a polymer material that can modify nano-drugs is able to extend circulatory time of doxorubicin and aspirin, enhance stability and reduce toxicity. At precancerous, aspirin will be released slowly to resist inflammation. When tumor cell appear at a more advance stage, doxorubicin release from Gel to achieve anti-tumor effect. After all those step, poly(ethylene glycol) could be expelled from body.
The medical records of adult patients who have received a technically successful PTBD will be screened sytematically in terms of bilirubin and GGT values in the follow up of 4 weeks after the intervention. Bilirubin and GGT values have been routinely examinated every 1 to 3 days. PTBD comprises external plastic endoprosthesis, combined external and internal endoprosthesis and primary metal stent insertion. The respective three procedures are considered separately. As PTBD is a rare intervention which is used after failed or impossible endoscopic retrograde cholangiopancreaticography (ERCP) medical records will be screened from 2002 to 2022 (20 years). It is expected that for example a decrease of GGT after three days might indicate a successful procedure. This in turn might has an impact on the early demission of the patient. On the other side, the precise definition of successful PTBD by bilirubin or GGT value might help to make this procedure better comparable to other alternative biliary drainage procedures such as endoscopic ultrasound-guided biliary drainage.
Community coaching is a a strategy that helps community leaders plan for and overcome challenges to community development. Interventions at the community level are most effective when they are conceived and led by locals. Community coaches can aid the local community in the development of FPCs in rural communities. FPCs have the potential to improve the nutritional quality of available food, and connect a diverse network of food system stakeholders from the public, private and nonprofit sectors, which includes local food pantries. Food pantry users are food insecure and avoid hunger by consuming low cost and shelf stable food items. Guided client choice is a system of distribution that can be employed in food pantries and supported by FPCs. Guided client-choice is a model of distribution in which pantry clients choose the foods they would like from the pantry based upon family size and is formatted based upon USDA MyPlate. Guided client choice has been shown to meet the needs of the pantry client base better than the traditional model of distribution often found in food pantries. Food pantries have the opportunity to meet the nutritional needs of the food insecure population.

Voices for Food is a multi-leveled socio-ecological, longitudinal, matched treatment and comparison study to develop food policy councils (FPCs), and improve food security and diet quality in rural communities. Voices for Food was conducted in 24 rural, high poverty counties in South Dakota, Indiana, Missouri, Michigan, Nebraska and Ohio. Counties were assigned to a treatment (n=12) or comparison (n=12) group.

Intervention activities focus on three key components that impact food security: 1) community coaching by Extension Educators/field staff, 2) FPC development, and 3) development of a MyChoice (guided client choice) food pantry. Community coaching, along with the Voices for Food kit was only provided to treatment counties. Comparison communities only received the Voices for Food kit. Evaluation components focus on three levels of the intervention: 1) Community (FPCs), 2) Food Pantry Organization and Food Environment, and 3) Pantry Client \& Families. Participants in this study were community stakeholders, food pantry directors, staff/volunteers and food pantry clients. Pantry food access/availability including pantry food quality and quantity, household food security and pantry client dietary intake are dependent variables.
PURPOSE: A method for preparing grape peel extract and a composition containing the same with an anti-obesity activity is provided to suppress secretion and accumulation of adipocytes. CONSTITUTION: A grape peel extract is prepared by extracting grape peel with 30-80% of spirit for 1-3 hours. A pharmaceutical composition for preventing or treating obesity contains the grape peel extract as an active ingredient. The pharmaceutical composition further contains carrier, excipient, and diluent. The pharmaceutical composition is administered solely or together with other materials. A health food composition for treating obesity contains the grape peel extract as an active ingredient.
The TPVB will be administered at the T4 level with the patient in the sitting position.The ultrasound probe will be placed 5 cm from the midline in the craniocaudal direction and moved medially to identify the transverse process and parietal pleura. The superior costotransverse ligament was identified as a collection of homogeneous linear echogenic bands alternating with echo-poor areas running from one transverse process to the next. Bubivacaine0.5%, 20 ml will be deposited in the space between the pleura and the costotransverse ligament.
Subjects will be men and women, 18-84 years of age, inclusive, who have been diagnosed with IBD. Each with a screening colonoscopy resulting in normal findings.
Use of 9, 10-anhydrodihydroartemisinin (9, 10-anhydrodihydroartemisinin) in preparation of medicine for preventing and treating multiple sclerosis is provided. In the study, we found that 9, 10-anhydrodihydroartemisinin (9, 10-anhydrodihydroartemisinine) can alleviate MS pathology by inhibiting the differentiation of Th17 and Th 1. Through the EAE animal model, we found that 9, 10-dehydrodihydroartemisinin-treated mice had significant relief of EAE symptoms, including lower clinical scores, reduced central nervous system leukocyte infiltration and reduced demyelination, compared to the control group. Also, the proportion of Th17 and Th1, which are the major pathogenic effector cells of MS, is markedly reduced in both the peripheral and central nervous systems. The secretion of IFN-gamma and IL-17 in the peripheral blood is also significantly reduced. The combined results show that 9, 10-dehydrodihydroartemisinin relieves the severity of EAE by reducing the differentiation rate of Th17 and Th 1. In summary, our data indicate that 9, 10-dehydrodihydroartemisinin has a key role in regulating the pathology of MS, and can provide a new alternative for MS treatment.
Patients attend a 2-day treatment program and complete questionnaires on study. Patients also have their medical records reviewed on study.
FIELD: microbiology, insecticides. SUBSTANCE: invention relates to preparing novel insecticide agents by microbiological synthesis. Method of preparing the compound used for killing insects or mites involves culturing one of strains Saccharopolyspora spinosa NRRL 18719, NRRL 18720 or NRLL 18823 in suitable nutrient medium under submerged condition followed by isolation of individual compounds. Composition containing an active substance and a carrier is developed based on the compound obtained. Using the prepared compounds and compositions insects or mites are killed by treatment of their resident regions. EFFECT: improved method of preparing, new agents indicated above, enhanced effectiveness of compound. 16 cl, 13 tbl, 19 ex
BACKGROUND: Dual antiplatelet therapy (DAPT) reduces ischemic events but increases bleeding risk, especially in patients with high bleeding risk (HBR). This study aimed to compare outcomes of abbreviated versus standard DAPT strategies in patients with HBR with acute coronary syndrome undergoing percutaneous coronary intervention.
METHODS AND RESULTS: Patients from the SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-Based Bare in Heart Disease Evaluated According to Recommended Therapies) registry with at least 1 HBR criterion who underwent percutaneous coronary intervention for acute coronary syndrome were identified and included. Patients were divided into 2 groups based on their planned DAPT time at discharge: 12-month DAPT or an abbreviated DAPT strategy and matched according to their prescribed P2Y12 inhibitor at discharge. The primary outcome assessed was time to net adverse clinical events at 1 year, which encompassed cardiac death, myocardial infarction, ischemic stroke, or clinically significant bleeding. Time to major adverse cardiovascular events and the individual components of net adverse clinical events were considered secondary end points. A total of 4583 patients were included in each group. The most frequently met HBR criteria was age older than 75 years (65.6%) and Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy score ≥25 (44.6%) in the standard DAPT group and oral anticoagulant therapy (79.6%) and age 75 years and older (55.2%) in the abbreviated DAPT group. There was no statistically significant difference in net adverse clinical events (12.9% versus 13.1%; hazard ratio [HR], 0.99 [95% CI, 0.88-1.11], P=0.83), major adverse cardiovascular events (8.6% versus 7.9%; HR, 1.08 [95% CI, 0.94-1.25]), or their components between groups. The results were consistent among all of the investigated subgroups.
CONCLUSIONS: In patients with HBR undergoing percutaneous coronary intervention due to acute coronary syndrome, abbreviated DAPT was associated with comparable rates of net adverse clinical events and major adverse cardiovascular events to a DAPT duration of 12 months.
Lisinopril tablets USP are indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta-blockers.

In using lisinopril tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril tablets USP does not have a similar risk. (See ). WARNINGS

In considering the use of lisinopril tablets USP, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in Black patients than in non-Blacks. In addition, ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients (see ). WARNINGS, Anaphylactoid and Possibly Related Reactions
A Chinese Mythic Fungus capsule is obtained through the steps of extracting sporophores of Mythic Fungus also named Ganoderma lucidum, clarifying an obtained comprehensive liquid for impurity removal, allowing a certain amount of impurity removed unbroken Mythic Fungus spores to penetrate, concentrating, disinfecting, drying, and crushing. Near two-hundred biochemical matters comprising polysaccharides, triterpenes, organic germanium, alkaloids, sterols, nucleosides, amino acids, proteins and the like which are naturally-synthesized effective compounds in the Mythic Fungus are extracted. Mythic Fungus becomes a solid having a special bitter taste and containing organic biochemical matters contained in an edible high-level fungus Mythic Fungus, and is processed to prepare the Chinese Mythic Fungus capsule. The Chinese Mythic Fungus capsule can prevent and treat hundreds of diseases comprising cancers, cardiovascular and cerebrovascular diseases and the like, is a high-level healthcare medicinal food having no additive and no toxic side effects, fills a gap in the Mythic Fungus product in the world from hundreds of years even everlasting, is an innovation of the scientific and technological theory in the world, and is an initiation of eating of fungal foods of Mythic Fungus and the like. The invention is protected by National Copyright Administration of the People's Republic of China, Copyright Law. The Mythic Fungus is a Chinese treasure, and promotes the health of humans.
End-stage renal disease (ESRD) patients are at increased risk of mortality, particularly due to cardiovascular events such as acute myocardial infarction. Hemodialysis and peritoneal dialysis are the two main treatment modalities for ESRD patients. Using data from the National Inpatient Sample (NIS) database, we conducted a retrospective study involving 25,435 ESRD patients diagnosed with ST-elevation myocardial infarction (STEMI) between 2016 and 2020, categorized by their dialysis regimen. Our analysis revealed comparable mortality rates between peritoneal dialysis (PD) and hemodialysis (HD) patients, but lower hospitalization costs and fewer complications among PD recipients. Over five years, we observed a notable decrease in STEMI mortality despite increased STEMI cases among HD patients. Conversely, HD patients experienced increased hospital stays and associated costs over the study period than PD patients, who demonstrated stable trends. This study highlights the implications of dialysis modality selection in managing costs and reducing morbidity among STEMI patients with ESRD.
The study are interested in the physiological foundation of the impact of aerobic exercise on cognitive performance in youth MDD subjects. Combined application of neurophysiological intervention and recording tools, including non-invasive brain stimulation, is suited to explore the impact of aerobic exercise on brain physiology and cognition in humans. We will apply transcranial magnetic stimulation (TMS) to obtain evoked potentials with electromyography (EMG) to explore cortical excitability. In the same participants, we will combine motor learning, working memory, and attention task to explore the association between the physiological effect of aerobic exercise and respective cognitive alterations. This project aims to explore the impact of aerobic exercise on cortical excitability and cognitive performance, and the association between these phenomena in youth MDD subjects. The study will improve our understanding of the role of aerobic exercise in cortical excitability, an important physiological basis for cognitive processes in humans, the underlying physiological mechanisms with regard to the aerobic exercise, and their functional relevance in youth MDD subjects.
AIM: We aimed to review all randomised controlled trial (RCT) data to explore optimal identification and treatment strategies of frail patients with Acute Coronary Syndromes (ACS).
METHODS: The protocol was preregistered (PROSPERO - CRD42021250235). We performed a systematic review including RCT's that 1; used at least one frailty assessment tool to assess frailty and its impact on outcomes in patients diagnosed with ACS and 2; used at least one intervention where change in frailty was measured in patients diagnosed with ACS. The Cochrane Central Register of Controlled Trials, MEDLINE and EMBASE were searched on the 1st April 2021 and updated on 4th July 2023. Owing to low search output results are presented as a narrative synthesis of available evidence.
RESULTS: A single RCT used a frailty assessment tool. A single RCT specifically targeted frailty with their intervention. This precluded further quantitative analysis. There was indication of selection bias against frail participants, and a signal of value for physical activity measurement in frail ACS patients. There was a high level of uncertainty and low level of robustness of this evidence.
CONCLUSIONS: Data from RCT's alone is inadequate in answering the reviews question. Future RCT's need to address ways to incorporate frail participants, whilst mitigating selection biases. Physical performance aspects of the frailty syndrome appear to be high yield modifiable targets that improve outcomes. Intervention trials should consider using change in frailty status as an outcome measure. Any trials that include frail participants should present data specifically attributable to this group.
PURPOSE: To form a rumen drug delivery device in a rolled configuration to be fixed in a shape by fixing a water-dispersible pressure sensitive adhesive to a repulpable tape having the adhesive on both its surfaces in a laminated structure made of a water-permeable substance exhibiting a low friction surface in the presence of water. CONSTITUTION: The improved means for constraining a rumen drug delivery device in a rolled configuration comprises a laminated structure made of a flexible water- permeable polymer substance held between two water-permeable substance (e.g. nitrocellulose) sheets exhibiting low friction surfaces in the presence of water. One side surface of the low friction surface is fixed to a repulpable tape double coated with water- dispersible pressure sensitive adhesive. For the purpose of strengthening an entangling of the device in a using environment, in the case of applying to the delivery device, a microperforation can be provided at a position in contact with or duplicated with the means. A manufacture of a device for a veterinary medication such as, for example, controlling and extending a delivery of an animal curing aninsecticide is facilitated.  A diameter and an array of the microperforation are selected to exhibit a sufficient internal section in a core sheet.
Participants receive fluticasone 50 mcg inhalation aerosol twice daily (BID) for 24 weeks and placebo to montelukast 4 mg QD for 24 weeks. Participants aged \>6 months to \<2 years receive placebo packet of OG QD for 24 weeks. Participants aged \>2 years to \<64 months receive placebo CT QD for 24 weeks.
Cerebral ischemia/reperfusion injury (CIRI) is a common feature of ischemic stroke leading to a poor prognosis. Effective treatments targeting I/R injury are still insufficient. The study aimed to investigate the mechanisms, by which glycyrrhizic acid (18β-GA) in ameliorates CIRI. Our results showed that 18β-GA significantly decreased the infarct volume, neurological deficit scores, and pathological changes in the brain tissue of rats after middle cerebral artery occlusion. Western blotting showed that 18β-GA inhibited the expression levels of phosphorylated JAK2 and phosphorylated STAT3. Meanwhile, 18β-GA increased LC3-II protein levels in a reperfusion duration-dependent manner, which was accompanied by an increase in the Bcl-2/Bax ratio. Inhibition of 18β-GA-induced autophagy by 3-methyladenine (3-MA) enhanced apoptotic cell death. In addition, 18β-GA inhibited the JAK2/STAT3 pathway, which was largely activated in response to oxygen-glucose deprivation/reoxygenation. However, the JAK2/STAT3 activator colivelin TFA abolished the inhibitory effect of 18β-GA, suppressed autophagy, and significantly decreased the Bcl-2/Bax ratio. Taken together, these findings suggested that 18β-GA pretreatment ameliorated CIRI partly by triggering a protective autophagy via the JAK2/STAT3 pathway. Therefore might be a potential drug candidate for treating ischemic stroke.
PURPOSE: A pharmaceutical composition containing Rubus fruticosus L.extract is provided to enhance antioxidant enzyme activation and to recover liver damage. CONSTITUTION: A pharmaceutical composition for preventing and treating hepatotoxicity diseases contains Rubus fruticosus L. extract as an active ingredient. The extract is isolated using water, low carbon number alcohol of C1-C3, or a mixture thereof. The low carbon number alcohol is ethanol or methanol. The hepatotoxicity diseases include drug-induced liver damage, viral liver damage, hepatitis, liver cirrhosis, liver cancer, or hepatic coma. A health food for preventing and treating hepatotoxicity diseases contains the extract as an active ingredient.
PURPOSE: An immune enhancer composition containing polymer emulsifier as a stabilizing agent and a vaccine composition containing the same are provided to continuously maintain immunity and to ensure formulation stability. CONSTITUTION: An immune enhancer composition contains oil ingredient, non-ionic emulsifier, aqueous ingredient and polymer emulsifier of A-B-A type block copolymer. A and B are denoted by chemical formula 1 and 2, respectively. The molecular weight of A and B is 500-50,000 each. A polymer emulsifier is contained in 0.1-5.0 weight% based on total weight. The immune enhancer is an emulsion of water-in-oil form. A vaccine composition contains the immune enhancer composition and biologically acceptable amount of immunogenic material.
The study is quasi-experimental study, which is being conducted in a private clinical settings in Khushab. Sample size of 20 individuals was calculated using Hamilton Depression Scale with effect size 0.97 G Power 3.1.9.2 software. The study participants will be screened first, then trained to perform SBE(1-minute maneuver). Participants will be instructed to stand upright and tighten their gluteal muscle and then ask them to put one foot in front of their body and placing most of their body weight on back foot. Then, ask them to breath in for three seconds simultaneously, by raising their hands in the air above their heads. After this, instruct them to exhale by using their whole body for pushing air out of the lungs. Participants will also guided to tighten all their body muscles while pushing air out. Exhale should last for seven seconds. The participants will also guided to repeat this procedure 3 times in one minute with resting period of 10 seconds. They will perform it 3 times a day for 3 months. Assessments will be taken at Baseline \& after 3 months.